admin – Page 6108 – Get News Story

Adrenoleukodystrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, by DelveInsight | Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Adrenoleukodystrophy pipeline constitutes 10+ key companies continuously working towards developing 11+ Adrenoleukodystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Adrenoleukodystrophy Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Adrenoleukodystrophy Market.

The Adrenoleukodystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Adrenoleukodystrophy Pipeline Report:

Companies across the globe are diligently working toward developing novel Adrenoleukodystrophy treatment therapies with a considerable amount of success over the years.
Adrenoleukodystrophy companies working in the treatment market are Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, Minoryx Therapeutics, and others, are developing therapies for the Adrenoleukodystrophy treatment

Emerging Adrenoleukodystrophy therapies such as – ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others are expected to have a significant impact on the Adrenoleukodystrophy market in the coming years.

Adrenoleukodystrophy Overview

Adrenoleukodystrophy (ALD) is a rare genetic disorder that affects the adrenal glands, the nervous system, and the myelin sheath of nerve cells in the brain. It primarily affects males and is caused by mutations in the ABCD1 gene located on the X chromosome.

Get a Free Sample PDF Report to know more about Adrenoleukodystrophy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/adrenoleukodystrophy-pipeline-insight

Emerging Adrenoleukodystrophy Drugs Under Different Phases of Clinical Development Include:

ABX-002: Autobahn Therapeutics
VK0214: Viking Therapeutics
SBT101: SwanBio Therapeutics
PXL065: Poxel SA
PXL770: Poxel SA
Leriglitazone : Minoryx Therapeutics
OP101 : Orpheris
Leriglitazone (MIN102): Minoryx Therapeutics

Route of Administration

Adrenoleukodystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intravenous
Subcutaneous
Oral
Intramuscular

Molecule Type

Products have been categorized under various Molecule types, such as

Monoclonal antibody
Small molecule
Peptide

Adrenoleukodystrophy Pipeline Therapeutics Assessment

Adrenoleukodystrophy Assessment by Product Type
Adrenoleukodystrophy By Stage and Product Type
Adrenoleukodystrophy Assessment by Route of Administration
Adrenoleukodystrophy By Stage and Route of Administration
Adrenoleukodystrophy Assessment by Molecule Type
Adrenoleukodystrophy by Stage and Molecule Type

DelveInsight’s Adrenoleukodystrophy Report covers around 11+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Adrenoleukodystrophy product details are provided in the report. Download the Adrenoleukodystrophy pipeline report to learn more about the emerging Adrenoleukodystrophy therapies

Some of the key companies in the Adrenoleukodystrophy Therapeutics Market include:

Key companies developing therapies for Adrenoleukodystrophy are – AstraZeneca, Cipla Inc., Abbott, Bayer AG, Merck KGaA, GlaxoSmithKline plc, agtc, bluebird bio, MINORYX THERAPEUTICS SL, SwanBio Therapeutics, Inc., Viking Therapeutics, Novartis AG, Sanofi, Pfizer Inc., Sumitomo Corporation, Johnson & Johnson Private Limited, and others.

Adrenoleukodystrophy Pipeline Analysis:

The Adrenoleukodystrophy pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Adrenoleukodystrophy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenoleukodystrophy Treatment.
Adrenoleukodystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Adrenoleukodystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenoleukodystrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Adrenoleukodystrophy drugs and therapies

Adrenoleukodystrophy Pipeline Market Drivers

Increasing awareness towards genetic diseases coupled with genetic counseling, rise in the number of R&D activities are some of the important factors that are fueling the Adrenoleukodystrophy Market.

Adrenoleukodystrophy Pipeline Market Barriers

However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Adrenoleukodystrophy Market growth.

Scope of Adrenoleukodystrophy Pipeline Drug Insight

Coverage: Global
Key Adrenoleukodystrophy Companies: Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, Minoryx Therapeutics, and others
Key Adrenoleukodystrophy Therapies: ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others
Adrenoleukodystrophy Therapeutic Assessment: Adrenoleukodystrophy current marketed and Adrenoleukodystrophy emerging therapies
Adrenoleukodystrophy Market Dynamics: Adrenoleukodystrophy market drivers and Adrenoleukodystrophy market barriers

Request for Sample PDF Report for Adrenoleukodystrophy Pipeline Assessment and clinical trials

Table of Contents

1	Adrenoleukodystrophy Report Introduction
2	Adrenoleukodystrophy Executive Summary
3	Adrenoleukodystrophy Overview
4	Adrenoleukodystrophy- Analytical Perspective In-depth Commercial Assessment
5	Adrenoleukodystrophy Pipeline Therapeutics
6	Adrenoleukodystrophy Late Stage Products (Phase II/III)
7	Adrenoleukodystrophy Mid Stage Products (Phase II)
8	Adrenoleukodystrophy Early Stage Products (Phase I)
9	Adrenoleukodystrophy Preclinical Stage Products
10	Adrenoleukodystrophy Therapeutics Assessment
11	Adrenoleukodystrophy Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Adrenoleukodystrophy Key Companies
14	Adrenoleukodystrophy Key Products
15	Adrenoleukodystrophy Unmet Needs
16	Adrenoleukodystrophy Market Drivers and Barriers
17	Adrenoleukodystrophy Future Perspectives and Conclusion
18	Adrenoleukodystrophy Analyst Views
19	Appendix
20	About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Adrenoleukodystrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, by DelveInsight | Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics

Ceramic Tiles Market to Gain 7.34% CAGR owing to Increase in Urbanization

“Skyquest Technology”

Ceramic Tiles Market Size, Share, Growth Analysis, By Finish(Glossy, Matte, Polished, Others), By Application(Wall tiles, and Floor tiles), By End Use(Residential, and Non-residential), By Region – Industry Forecast 2024-2031

Ceramic Tiles Market size was valued at USD 245.50 billion in 2022 and is poised to grow from USD 263.52 Billion in 2023 to USD 464.41 Billion by 2031, at a CAGR of 7.34% over the forecast period (2024–2031).

The rising demand from residential, commercial, and industrial applications is expected to propel the growth of the global ceramic tiles market over the forecast period. Flooring is the primary application for ceramic tiles. They are perfect for flooring due to their affordability, simplicity of application, and availability in a range of forms and sizes. The main reason for using ceramic tiles in interior design is that they are cheaper and more attractive. The state-of-the-art ceramic tiles manufacturers are expected to produce more investment by the industry since the real estate is being designed in line with green models. The international market necessitates products and services meeting credible sustainability benchmarks as it has more environmental constraints.

Download a detailed overview:

https://www.skyquestt.com/sample-request/ceramic-tiles-market

Fierce Battle with a Focus on Innovation and Eco-Friendly Solutions

Some of the primary participants in the fiercely contested global ceramic tiles market include Mohawk Industries, Inc., Kajaria Ceramics, and Grupo Lamosa. This is achieved by creating advanced items, expanding broad distribution setup, taking strategic mergers and acquisitions into account among other things. They also invest in ecofriendly manufacturing methods as a response to the growing desire for green products by customers. Moreover, regional champions play a vital role in meeting local preferences and providing cheaper options. Urbanization and infrastructure growth have caused the market segmentation grounding on the product type, application, and the end users, with majority of the demand being driven by residential and commercial sectors.

Major Players are Redefining the Competitive Landscape in the Ceramic Tiles Industry

The fiercelycompetitive global ceramic tiles market has several big rivals including Mohawk Industries, Inc., Kajaria Ceramics, and Grupo Lamosa. They have established robust distribution networks, produced new goods and engaged in mergers and acquisitions at the right time, with the aim of increasing their market presence. The increasing demand for sustainable products is consistent with an emphasis on ecologically responsible means of producing goods.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/ceramic-tiles-market

Local tastes are taken into account by regional businesses which makes them equally important for providing affordable solutions. In this regard, global urbanization and infrastructure development have resulted in high demand in the residential and commercial sectors, retail market segmentation as per production type, application and end-user.

The Strategic Acquisitions and Green Innovations of Industry Leaders

Mohawk Industries has improved its position in the worldwide ceramic tiles market by making calculated acquisitions, such the acquisition of Marazzi Group. Kajaria Ceramics prioritises innovation in its product line, which includes the Ultima collection, which is renowned for its exceptional durability and visual appeal.Grupo Lamosa’s market share expanded by purchasing Ceramica San Lorenzo which is a European tile maker. The latter ones of these groups give priority to sustainability where Mohawk for instance produce environmentally friendly tiles using recycled materials. It also involves local options known as regional players like Guangdong Dongpeng Company from China which concerns affordability and crossovers with local cultures; hence raising competition within this industry. Significant demand is generated by infrastructure projects and urbanisation in the Asia-Pacific region, which supports the market’s expansion.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/ceramic-tiles-market

Sustainable Strategies for Ceramic Tiles in a Rapidly Urbanizing World

Rising demand from the commercial, industrial, and residential sectors is expected to fuel the strong expansion of the ceramic tiles market globally. Floors remain as the leading utilization area majorly as they are cheap, easy to install and have variants in designs, such as ceramic tiles. The growth in the construction sector is forcing enterprises to adhere strictly to the environmentally friendly ways of producing goods to ensure sustainability. Mohawk Industries, Kajaria Ceramics, Grupo Lamosa and other industry leaders are expanding to more markets using inventions, thought acquisitions, large distribution networks. They focus on offering personalized yet cheap solutions whereby the small players greatly contribute towards higher espousal of competition.

Related Reports:

Digital Twin Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/ceramic-tiles-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ceramic Tiles Market to Gain 7.34% CAGR owing to Increase in Urbanization

Acute Pancreatitis Pipeline Analysis 2024: FDA Approvals and Emerging Therapies by DelveInsight | Dynavax Tech, Fresenius SE, GlaxoSmithKline, Abbott, B. Braun SE, Baxter

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acute Pancreatitis pipeline constitutes 4+ key companies continuously working towards developing 4+ Acute Pancreatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Acute Pancreatitis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Pancreatitis Market.

Some of the key takeaways from the Acute Pancreatitis Pipeline Report:

Companies across the globe are diligently working toward developing novel Acute Pancreatitis treatment therapies with a considerable amount of success over the years.
Acute Pancreatitis companies working in the treatment market are Panafina, Inc., CalciMedica, Inc., SCM Lifescience Co., Pfizer, Repligen Corporation, Regeneron Pharmaceuticals, and others, are developing therapies for the Acute Pancreatitis treatment

Emerging Acute Pancreatitis therapies in the different phases of clinical trials are- RABI-767, CM4620, SCM-AGH, meropenem, RG1068, evinacumab, and others are expected to have a significant impact on the Acute Pancreatitis market in the coming years.
In April 2024, CalciMedica has successfully completed patient enrollment for its Phase IIb CARPO clinical trial, aimed at assessing the effectiveness of Auxora in treating acute pancreatitis. Auxora, a new therapy from CalciMedica, is a powerful and selective inhibitor of Orai1-containing calcium release-activated calcium (CRAC) channels. This treatment is being developed to address acute inflammatory and immunologic conditions, with a particular emphasis on its potential advantages for patients with acute pancreatitis.

Acute Pancreatitis Overview

Acute pancreatitis is a sudden inflammation of the pancreas, an organ located behind the stomach that plays a critical role in digestion and blood sugar regulation. The condition can range from mild discomfort to a severe, life-threatening illness.

Get a Free Sample PDF Report to know more about Acute Pancreatitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-pancreatitis-pipeline-insight

Emerging Acute Pancreatitis Drugs Under Different Phases of Clinical Development Include:

RABI-767: Panafina, Inc.
CM4620: CalciMedica, Inc.
SCM-AGH: SCM Lifescience Co.
RABI-767: Panafina, Inc.
meropenem: Pfizer
RG1068: Repligen Corporation
evinacumab: Regeneron Pharmaceuticals

Acute Pancreatitis Route of Administration

Acute Pancreatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intravenous
Subcutaneous
Oral
Intramuscular

Acute Pancreatitis Molecule Type

Acute Pancreatitis Products have been categorized under various Molecule types, such as

Monoclonal antibody
Small molecule
Peptide

Acute Pancreatitis Pipeline Therapeutics Assessment

Acute Pancreatitis Assessment by Product Type
Acute Pancreatitis By Stage and Product Type
Acute Pancreatitis Assessment by Route of Administration
Acute Pancreatitis By Stage and Route of Administration
Acute Pancreatitis Assessment by Molecule Type
Acute Pancreatitis by Stage and Molecule Type

DelveInsight’s Acute Pancreatitis Report covers around 4+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Acute Pancreatitis product details are provided in the report. Download the Acute Pancreatitis pipeline report to learn more about the emerging Acute Pancreatitis therapies

Some of the key companies in the Acute Pancreatitis Therapeutics Market include:

Key companies developing therapies for Acute Pancreatitis are – Dynavax Technologies Corporation, Fresenius SE & Co. KGaA, GlaxoSmithKline, Abbott Laboratories, B. Braun SE, Baxter International Inc., CalciMedica Inc., Merck & Co., Inc, Olympus Corporation, Pfizer Inc., SCM Lifescience, and others.

Acute Pancreatitis Pipeline Analysis:

The Acute Pancreatitis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Acute Pancreatitis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Pancreatitis Treatment.
Acute Pancreatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Acute Pancreatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Pancreatitis market.

Download Sample PDF Report to know more about Acute Pancreatitis drugs and therapies

Acute Pancreatitis Pipeline Market Drivers

Increasing Incidence of Acute Pancreatitis, Advancements in Diagnostic Techniques, Development of Novel Therapies, Growing Awareness and Education, Improved Healthcare Infrastructure, are some of the important factors that are fueling the Acute Pancreatitis Market.

Acute Pancreatitis Pipeline Market Barriers

However, High Cost of Treatment, Limited Availability of Specialized Care, Side Effects and Complications of Treatments, Lack of Standardized Treatment Protocols, Challenges in Early Diagnosis , and other factors are creating obstacles in the Acute Pancreatitis Market growth.

Scope of Acute Pancreatitis Pipeline Drug Insight

Coverage: Global
Key Acute Pancreatitis Companies: Panafina, Inc., CalciMedica, Inc., SCM Lifescience Co., Pfizer, Repligen Corporation, Regeneron Pharmaceuticals, and others
Key Acute Pancreatitis Therapies: RABI-767, CM4620, SCM-AGH, meropenem, RG1068, evinacumab, and others
Acute Pancreatitis Therapeutic Assessment: Acute Pancreatitis current marketed and Acute Pancreatitis emerging therapies
Acute Pancreatitis Market Dynamics: Acute Pancreatitis market drivers and Acute Pancreatitis market barriers

Request for Sample PDF Report for Acute Pancreatitis Pipeline Assessment and clinical trials

Table of Contents

1. Acute Pancreatitis Report Introduction

2. Acute Pancreatitis Executive Summary

3. Acute Pancreatitis Overview

4. Acute Pancreatitis- Analytical Perspective In-depth Commercial Assessment

5. Acute Pancreatitis Pipeline Therapeutics

6. Acute Pancreatitis Late Stage Products (Phase II/III)

7. Acute Pancreatitis Mid Stage Products (Phase II)

8. Acute Pancreatitis Early Stage Products (Phase I)

9. Acute Pancreatitis Preclinical Stage Products

10. Acute Pancreatitis Therapeutics Assessment

11. Acute Pancreatitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Pancreatitis Key Companies

14. Acute Pancreatitis Key Products

15. Acute Pancreatitis Unmet Needs

16 . Acute Pancreatitis Market Drivers and Barriers

17. Acute Pancreatitis Future Perspectives and Conclusion

18. Acute Pancreatitis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Pancreatitis Pipeline Analysis 2024: FDA Approvals and Emerging Therapies by DelveInsight | Dynavax Tech, Fresenius SE, GlaxoSmithKline, Abbott, B. Braun SE, Baxter

Carbon Capture, Utilization, and Storage (CCUS) Market to Grow at CAGR 11.8% by 2031 Driven by Enhanced Climate Goals and Investment Incentives

“Skyquest Technology”

Carbon Capture, Utilization and Storage Market Size, Share, Growth Analysis, By Services(Capture, Transportation, Utilization, and Storage), By Technology(Pre-combustion, Post-combustion, Oxy-combustion, and Industrial Process), By End-Use Industry(Oil & Gas, Power Generation, Chemicals & Petrochemicals, Cement), By Region – Industry Forecast 2024-2031

Carbon Capture, Utilization and Storage Market size was valued at USD 2.26 billion in 2022 and is expected to rise from USD 2.52 billion in 2023 to reach a value of USD 6.16 billion by 2031, at a CAGR of 11.8% during the forecast period (2024–2031).

The global Carbon Capture, Utilization and Storage Market is highly favorable for companies like power generation industries and oil & gas industries. Growing focus on lessening CO2 emissions and rising demand for CO2-EOR techniques to reduce the greenhouse impact is making the market progress at an exceptional rate.

Carbon Capture, Utilization and Storage is the sole set of technologies used to reduce emissions in the major sectors and to eliminate Co2 to stabilize the challenging emissions. This is an essential component of the ‘Net’ zero Goals. After many years of slow-moving developments, Carbon Capture, Utilization and Storage (CCUS) is gaining new impetus thanks to enhanced climate goals and improved investment incentives. Power and industrial plants already in place can be replaced with CCUS to enable continuous operation. It proved its efficiency in lowering emissions mainly in the industries that find it difficult to reduce emissions, comprisingsteel, chemicals, and cement.

Download a detailed overview:

https://www.skyquestt.com/sample-request/carbon-capture-and-storage-market

Capital Raise Essential for New Companies to Flourish in the Market

CCUS has provided an inclusive strategy to reduce Co2 emissions from power generation and industrial activities. Besides, it creates zero emissions with the help of technologies like direct Air Capture and bioenergy with CCS. Businesses can use CCUS to reduce their carbon footprint and shift towards low-carbon systems by holding CO2 from the air or the circular network concepts, utilizing in numerous applications, and storing it underground safely. The adoption of CCUS holds great potential in multiple industries soon. The market is also witnessingheavy investments with the growing awareness by the government and businesses realizing the importance of concern for climate change. CCUS technology will become an important part of de-carbonization strategies on the global scale in future.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/carbon-capture-and-storage-market

A global group of energy and petrochemical companies, Shell, has led Northern Lights, a huge industrial decarbonization plan of action. The company also includes Equinor, and Total Energies with support from the Norwegian government. Known as ‘the only cross-border open-source carbon dioxide transport and storage infrastructure network,’ the project adopts a cutting-edge shipping and subsea storage system to reduce emissions from industrial processes. Northern Lights was financed by the EU in January 2022 to conduct expansion studies.
ExxonMobil and FuelCell Energy have been developing a system to prevent CO2 from being released into the atmosphere. The device uses carbonated fuel cells to capture CO2 from the plant’s drain. Carbonate fuel cellswill be involved in technologies by ExxonMobil, offeringintegrated CCUS solutionsfor clients. It will deliveralternatives toeconomic de-carbonization,aiming atreceiving net-zero emissions for society.
The leading industrial group, MHI Group,offers its Groupwide knowledge to the project, helping in the production of a CCUS value chain, spanning water and land. Superior gas handling technologies gathered by Mitsubishi Heavy Industries Engineering, widely used carbon capture techniques and Mitsubishi Shipbuilding Co., Ltd.’s building of liquefied gas carriers.
In February2024, Fluor Corporation,stated that it had received a license by Chevron New Energies. The deal aims to reduce CO2 emissions at operations in Chevron’s Eastridge Cogeneration inCalifornia, withits exclusive Econamine FG PlusSM carbon capture technology.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/carbon-capture-and-storage-market

CCUS holds huge potential in the coming years as a key component in energy transition. With innovations, cultivating and deploying 3D experience platform, the public as well as the leaders can wholly realizeCCUS’s promise and guide in a strong and sustainable future.

Related Reports:

3D Printing Market

Visit Our Website: https://www.skyquestt.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Carbon Capture, Utilization, and Storage (CCUS) Market to Grow at CAGR 11.8% by 2031 Driven by Enhanced Climate Goals and Investment Incentives

Cancer Gene Therapy Market to Grow at a Robust CAGR 20.42% by 2031 Innovations in Combination Therapies Drive Future Potential

“Skyquest Technology”

Cancer Gene Therapy Market Size, Share, Growth Analysis, By Therapy(Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer), By Indication(Breast Cancer, Ovarian Cancer, Liver Cancer, Pancreatic Cancer), By End User(Hospitals, Diagnostic centers, Research Institutes, and Others), By Region – Industry Forecast 2024-2031

Cancer Gene Therapy Market size was valued at USD 2.38 billion in 2022 and is poised to grow from USD 2.86 billion in 2023 to USD 12.63 billion by 2031, growing at a CAGR of 20.42% in the forecast period (2024-2031).

The global Cancer Gene Therapy Market is a very promising and gaining huge popularity due to its high success rate in preclinical as well as clinical trials. Also, the existing research and development strategies implemented by the pharmaceutical firms to develop novel drugs is trending in the market.

Combination therapies integrating vaccinations are expected to be more effective than just vaccine alone. Vaccinations for cancer that only developed slight immune response could support as an additional treatment used along with surgery or chemotherapy to remove the present cancer cells. With the continuing clinical trials, gene therapy cancer injections or vaccines could soon reach their full potential. As the early stages of vaccine research are winding up, it is possible that soon there will be cancer treatments that work and include vaccinations in the treatment plan.

Download a detailed overview:

https://www.skyquestt.com/sample-request/cancer-gene-therapy-market

Growing Number of Novel Therapeutic Approaches to Drive the Market

Gene therapy holds can capably use numerous unique genes like any suicidal gene, siRNA gene, anti-angiogenesis, immunotherapeutic gene, gene-directed enzyme prodrug, and oncolytic gene. Also, the market is witnessing novel therapeutic methods by the developments in gene transfer techniques. This supports the established treatments of cancer that directly modify the DNA. There are extensive studies made by preclinical research for better aiming and tumor-selective expression. However, multiple problems are still present before these techniques can be used on patients.

McKinsey launchesa novel Digital Capability Center for encouraging the production of gene &cell therapies. The new Digital Capability Center will focus on uplifting operational productivity and digital revolutions in bio-pharma production in partnership with NJII.
Sino Biological, Inc., a biotechnology company, and InDevR, Inc., a leader in analytical solutions for vaccine in-process and quality control testing, today announced a new conglomeration to speed up the progress of multiplexed assays for a wider range of vaccine, mRNA therapies, and cell and gene therapy applications.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/cancer-gene-therapy-market

CGT Catapult, an independent innovation and technology organization, and Cellular Origins, a TTP Company focused on enabling scalable, efficient, and cost-effective manufacture of CGTs, today announced a collaboration to demonstrate universal automation of CGT manufacturing. The cooperation will physically and digitally integrate the current bioprocessing equipment using Cellular Origins’ Constellation robotic platform at the CGT Catapult’s Stevenage (MIC) Manufacturing Innovation Centre.
A group of electrical engineering experts at the University of Wisconsin, in Madison have created a stimulating technique that may increase the body’s receptiveness to specific gene therapies, thereby improving the administration of expensive medical treatments. When liver cells were exposed to short-term electric pulses, as opposed to cells that were not open to pulsed electric fields, the liver cells absorbed over 40 times the amount of gene therapy material. This will increase safety and drive cost effectiveness by reducing the dosage needed.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/cancer-gene-therapy-market

Gene therapy is a fresh medical experiment holding promises for cancer treatment. It can treat cancer in 2 different ways: either by reversing the harmful mutations causing cancer in the first place or by directly attacking the cancer cells. Previous technologies, such as CAR-T are widely utilized for cancer treatment, and the latter, gene replacement is in the research phase owing to complexexpensive nature and genetic makeup. As the technologies improve, it will be adopted expansively, reducing its cost and driving itsaffordability.

Related Reports:

Blockchain Market

Visit Our Website: https://www.skyquestt.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cancer Gene Therapy Market to Grow at a Robust CAGR 20.42% by 2031 Innovations in Combination Therapies Drive Future Potential

Hyperoxaluria Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies by DelveInsight | Alnylam Pharma, Genentech, Dicerna Pharma, Pfizer Inc., Zhejiang Tianxin Pharma, Wuxi Further Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hyperoxaluria pipeline constitutes 9+ key companies continuously working towards developing 10+ Hyperoxaluria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Hyperoxaluria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Hyperoxaluria Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hyperoxaluria Market.

Some of the key takeaways from the Hyperoxaluria Pipeline Report:

Companies across the globe are diligently working toward developing novel Hyperoxaluria treatment therapies with a considerable amount of success over the years.
Hyperoxaluria companies working in the treatment market are Alnylam Pharmaceuticals, Biocodex, Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others, are developing therapies for the Hyperoxaluria treatment

Emerging Hyperoxaluria therapies in the different phases of clinical trials are- Lumasiran, nedosiran, Stiripentol Oral Capsule, DCR-PHXC, CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others are expected to have a significant impact on the Hyperoxaluria market in the coming years.
In October 2023, Novo Nordisk has gained approval from the US Food and Drug Administration (FDA) for Rivfloza (nedosiran) injection. This treatment aims to lower urinary oxalate levels in children aged nine and older, as well as adults with primary hyperoxaluria type 1 (PH1) who have relatively preserved kidney function. PH1 is a rare genetic disorder causing the liver to overproduce oxalate, affecting about one in 38,600 people globally. The approval covers Rivfloza dosages of 80mg, 128mg, or 160mg, administered monthly via subcutaneous ribonucleic acid interference therapy. This decision was based on data from the pivotal Phase II PHYOX2 clinical trial and interim results from the ongoing Phase III PHYOX3 extension study.
In July 2023, BioMarin has completed the multi-ascending dose study of BMN 255 for hyperoxaluria in chronic liver disease in healthy volunteers. Early data showed a rapid and significant increase in plasma glycolate following BMN 255 treatment. BioMarin plans to begin enrolling patients with chronic liver disease and hyperoxaluria in an expanded study in the second half of 2023. The company believes that BMN 255, a potent, orally bioavailable small molecule, could significantly reduce the disease and treatment burden for this patient population with significant unmet needs.

Hyperoxaluria Overview

Hyperoxaluria is a medical condition characterized by an excessive amount of oxalate in the urine. Oxalate is a natural substance found in many foods, and it is also produced by the liver. When there is too much oxalate in the urine, it can combine with calcium to form kidney stones, which can cause significant pain and urinary issues.

Get a Free Sample PDF Report to know more about Hyperoxaluria Pipeline Therapeutic Assessment

https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight

Emerging Hyperoxaluria Drugs Under Different Phases of Clinical Development Include:

Lumasiran: Alnylam Pharmaceuticals
Stiripentol Oral Capsule: Biocodex
DCR-PHXC: Dicerna Pharmaceuticals
CHK-336: Chinook Therapeutics
BBP-711: Cantero Therapeutics
BMN 255: BioMarin Pharmaceutical, Inc
Oxabact: OxThera
Nedosiran: Dicerna Pharmaceuticals, Inc.

Hyperoxaluria Route of Administration

Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical
Molecule Type

Hyperoxaluria Molecule Type

Hyperoxaluria Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Hyperoxaluria Pipeline Therapeutics Assessment

Hyperoxaluria Assessment by Product Type
Hyperoxaluria By Stage and Product Type
Hyperoxaluria Assessment by Route of Administration
Hyperoxaluria By Stage and Route of Administration
Hyperoxaluria Assessment by Molecule Type
Hyperoxaluria by Stage and Molecule Type

DelveInsight’s Hyperoxaluria Report covers around 8+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Hyperoxaluria product details are provided in the report. Download the Hyperoxaluria pipeline report to learn more about the emerging Hyperoxaluria therapies

Some of the key companies in the Hyperoxaluria Therapeutics Market include:

Key companies developing therapies for Hyperoxaluria are – Alnylam Pharmaceuticals, Inc., Genentech, Inc., Dicerna Pharmaceuticals, Inc., Pfizer Inc., Zhejiang Tianxin Pharmaceutical Co., Wuxi Further Pharmaceutical Co Ltd, Tecoland Corporation, Takeda Pharmaceuticals Company Limited, Intellia Therapeutics, Inc., and others.

Hyperoxaluria Pipeline Analysis:

The Hyperoxaluria pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Hyperoxaluria with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hyperoxaluria Treatment.
Hyperoxaluria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hyperoxaluria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hyperoxaluria market.

Download Sample PDF Report to know more about Hyperoxaluria drugs and therapies

Hyperoxaluria Pipeline Market Drivers

Rising Prevalence of Hyperoxaluria, increasing demand of disease specific novel treatment are some of the important factors that are fueling the Hyperoxaluria Market.

Hyperoxaluria Pipeline Market Barriers

However, high cost of treatment and diagnosis for Hyperoxaluria, limited research and development for treatment and other factors are creating obstacles in the Hyperoxaluria Market growth.

Scope of Hyperoxaluria Pipeline Drug Insight

Coverage: Global
Key Hyperoxaluria Companies: Alnylam Pharmaceuticals, Biocodex, Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others
Key Hyperoxaluria Therapies: Lumasiran, nedosiran, Stiripentol Oral Capsule, DCR-PHXC, CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others
Hyperoxaluria Therapeutic Assessment: Hyperoxaluria current marketed and Hyperoxaluria emerging therapies
Hyperoxaluria Market Dynamics: Hyperoxaluria market drivers and Hyperoxaluria market barriers

Request for Sample PDF Report for Hyperoxaluria Pipeline Assessment and clinical trials

Table of Contents

1. Hyperoxaluria Report Introduction

2. Hyperoxaluria Executive Summary

3. Hyperoxaluria Overview

4. Hyperoxaluria- Analytical Perspective In-depth Commercial Assessment

5. Hyperoxaluria Pipeline Therapeutics

6. Hyperoxaluria Late Stage Products (Phase II/III)

7. Hyperoxaluria Mid Stage Products (Phase II)

8. Hyperoxaluria Early Stage Products (Phase I)

9. Hyperoxaluria Preclinical Stage Products

10. Hyperoxaluria Therapeutics Assessment

11. Hyperoxaluria Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hyperoxaluria Key Companies

14. Hyperoxaluria Key Products

15. Hyperoxaluria Unmet Needs

16 . Hyperoxaluria Market Drivers and Barriers

17. Hyperoxaluria Future Perspectives and Conclusion

18. Hyperoxaluria Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hyperoxaluria Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies by DelveInsight | Alnylam Pharma, Genentech, Dicerna Pharma, Pfizer Inc., Zhejiang Tianxin Pharma, Wuxi Further Pharma

Opera22 Unveils New Synth-Wave/Electronic Single, “Flex in the City”

Fans and followers everywhere can listen to “Flex in the City” on iTunes and Spotify

The anonymous musical trio behind Opera22 is back again with a brand new single. “Flex in the City” has made its official debut today, and people everywhere can stream this out-of-this-world new track on iTunes and Spotify now.

Fun, lighthearted, and quirky – Opera22 amuses its fans and followers via the group’s Instagram page. When it’s time to make music, however, this trio does nothing less than impress.

In March 2022, three friends sat together for a dinner that would spark the idea for Opera22. They wanted to inject their humor and lightheartedness into a project that would spread meaningful, positive messages. They decided to take their music in a very different direction. The three friends decided they would create Opera22 and remain anonymous, thereby directing focus on the music as opposed to the members. The trio got to work setting up an Instagram page and making music.

Opera22 debuted its first single, “Your Curriculum Vitae” in 2023, inspiring listeners to consider the priorities in their lives and focus on what truly matters.

Now, Opera22 has released another single that stirs the mind. “Flex in the City” has a captivating beat with electronic and synth styling that keeps listeners engaged throughout. The theme for “Flex in the City” is mocking the stereotype of the macho man. As a song with no lyrics or vocals, “Flex in the City” does an outstanding job of catching the attention of its listeners with just a few simple yet somewhat addictive sound elements.

Production and mixing for “Flex in the City” were completed by Fabio Carbotta, and the mastering of the track was done by Giovanni Versari.

Listen to “Flex in the City” now on Spotify and iTunes, and stay up to date with the latest from Opera22 by visiting their Instagram page.

ABOUT OPERA22

Opera22 is a synth-wave/electronic group created by a trio of anonymous artists to spread joy and positivity through music.

Follow Opera22 on Instagram: @opera22_official

Media Contact
Company Name: Opera22
Contact Person: Federico Palmieri
Email: Send Email
Phone: +393408552442
Country: United States
Website: https://www.instagram.com/opera22_official/

Cloud Computing Market to Gain 15.1% CAGR, due to Growing use of Big Data

“Skyquest Technology”

Cloud Computing Market Size, Share, Growth Analysis, By Service(Software As A Service ( Customer Relationship Management, Enterprise Resource Management, Human Capital Management, Content Management), By Deployment Mode(Private Cloud, Public Cloud, and Hybrid Cloud), By Enterprise Size(Large Enterprises, and Small & Medium Enterprise), By End-use(IT &ITES ( Devops, Big Data And Analytics, IT Security And Compliance, Others)), By Region – Industry Forecast 2024-2031

Cloud Computing Market size was valued at USD 626.4 billion in 2022 and is poised to grow from USD 720.99 billion in 2023 to USD 2220.9 billion by 2031, growing at a CAGR of 15.1% during the forecast period (2024-2031).

Ashigh-level computing, cheap total cost of ownership, utility-based sharing models, security, and data management, cloud services help the global cloud computing marketoperate more effectively. Additionally, by enabling companies to utilize AI capabilities, the adoption of cutting-edge technologies like machine learning and artificial intelligence (AI) promotes cloud growth. Cloud computing enables firms to work and respond to changing market conditions m quickly and efficiently than would have been possible without it. It simplifies consumerization of technology. It has created new ways of developing highly engaging customer experiences that were never there before. Cloud computing has changed the behaviors of both people and firms thereby allowing many industries bypass technical hurdles.

Download a detailed overview:

https://www.skyquestt.com/sample-request/cloud-computing-market

Unpacking the Strategies in the Ever-Evolving Cloud Computing Realm

Key competitors in the global cloud computing market, including Google Cloud Platform (GCP), Microsoft Azure, and Amazon Web Services (AWS), define a dynamic competitive landscape. Several huge corporations dominated this market – manufacturing, healthcare, finance, and retail. Despite offering a vast range of services and strong infrastructure, AWS is leading the way. As far as machine learning + data analytics are concerned, GCP is best known while hybrid clouds + enterprise services are Azure’s strong sides. Recently, entrants to cloud computing have been driving innovation and competition by focusing on certain areas within this ecosystem.

Exploring the Triumphs of AWS, Azure, and GCP in Global Business Arenas

Key firms with various strengths, such as Microsoft Azure, Google Cloud Platform, and Amazon Web Services (AWS), dominate the global cloud computing market. AWS leads the market due to an extensive service offering and robust infrastructure. GCP stands out as far as machine learning skills and data analytics are concerned, while Azure excels in hybrid cloud solution and enterprise services.

The trio comprising of finance, healthcare, manufacturing and retail shapes the competitive environment in diverse industry sectors. New global firms and specialty suppliers add to the dynamic ecology, stimulating global rivalry and encouraging innovation.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/cloud-computing-market

Triumphs in the Digital Domain with Next-Generation Cloud Offerings

For example, Amazon Web Services (AWS) maintains its leadership position by providing a wide range of services, including sturdy infrastructure like AWS data centres and solutions like Amazon EC2 and S3. Microsoft Azure is certainly the alpha dog in hybrid cloud solutions due to its Azure Stack that allows smooth communication between on-premises and cloud environments making it ideal for business-applications. Google Cloud Platform (GCP) on the other hand proves its command over data analytics and machine learning by making use of technologies such as BigQuery as well as TensorFlow. This guarantees that businesses will get cutting edge ideas other than the power to think like humans. These examples show why AWS and GCP have such high market share when it comes to different competition groups within cloud computing at the global level as well as industries.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/cloud-computing-market

Mastering the Digital Frontier through Reshaping Cloud Computing Landscape

Cloud services, which provide safe data management, cost-effectiveness, and high-level computing, transform company processes. Their AI capabilities and utility-based sharing models ease the consumerization of technology while improving flexibility to market changes. Beyond the limitations of technology, cloud computing offers compelling customer experiences and revolutionises the way both individuals and corporations conduct business. With their respective advantages, the trio of AWS, Azure, and GCP controls most of the worldwide cloud market. With its wide range of services, AWS dominates; Azure is great at hybrid solutions; and GCP is outstanding at AI and data analytics. Their impact permeates important industries, stimulating innovation and escalating international rivalry.

Visit Our Website: https://www.skyquestt.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cloud Computing Market to Gain 15.1% CAGR, due to Growing use of Big Data

July 2024 Hot Small-Cap Stocks Under $5 Gaining Now: KAVL, VTAK, INBS, BSFC, PRSO

Kaival Brands Innovations Group Inc. (NASDAQ: KAVL): The exclusive U.S. distributor of BIDI® Stick and global distributor of VEEBA® through Philip Morris Products SA (NYSE: PM), raised approximately $6 million through a public offering on June 24. The stock is up 26.44% since June 21, 2024. The proceeds will support working capital, corporate purposes, operations, and business expansion.

Catheter Precision Inc. (NYSE American: VTAK): Gained attention after announcing its first purchase order from Qatar following an evaluation of its VIVO product. Trading volumes have surged, positioning the stock in breakout territory, up 25.2% in June 2024. The VIVO system aids in identifying ventricular arrhythmias before procedures, while the LockeT closure retention device enhances patient care.

Intelligent Bio Solutions Inc. (NASDAQ: INBS): Signed two major UK warehouse and logistics customers, implementing Intelligent Fingerprinting Drug Screening. The company began dosing for its FDA-supporting pharmacokinetic study, expecting results by the end of July, following a shift to a global operations framework.

Blue Star Foods Corp (NASDAQ: BSFC): An international seafood company specializing in refrigerated pasteurized crab meat and other premium seafood products. The stock surged over 100%, trading above $3.50 per share, driven by a forecast of at least 65% revenue growth in 2024 and an annual run-rate exceeding $20 million. The company’s positive outlook is attributed to product line expansion, increased market penetration, and strengthened distribution channels.

Peraso Inc. (NASDAQ: PRSO): Introduced a new wireless platform for secure tactical communications using 60 GHz mmWave technology, featured in “MicrowaveJournal.” The platform supports low-latency, high-bandwidth applications, opening opportunities in the defense sector. Fiscal Q1 2024 results showed net revenue of $2.8 million, up from $1.8 million the previous quarter. The technology is integrated into Panasonic Corporation’s (Tokyo: 6752.T) (OTC: PCRFF) systems across Japan.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: July 2024 Hot Small-Cap Stocks Under $5 Gaining Now: KAVL, VTAK, INBS, BSFC, PRSO

SeedHunter Celebrates Launch of Marketing Module with Exclusive Dubai Event

“GOLIATH VENTURES INC. & GOLIATH INTERNATIONAL GROUP is an international firm that develops blockchain technology projects, operates and builds crypto liquidity pools and manages Bitcoin mining infrastructure.”

SeedHunter recently hosted an exclusive event in Dubai to celebrate the launch of the highly anticipated Marketing Module. The event brought together community members, Key Opinion Leaders (KOLs), investors, and crypto project managers, all sharing a commitment to enhancing the Web3 ecosystem through the platform.

Set against the stunning backdrop of the Five Jumeirah Village resort’s penthouse, attendees enjoyed breathtaking views of the Burj al Arab, Marina Skyline, and the Burj Khalifa from the outdoor pool area.

A total of 72 influential figures from the crypto community were graciously invited to join the festivities marking the Marketing Module’s debut. The event attracted a select group of guests, including investors, KOLs, and entrepreneurs, reflecting its high demand. Noteworthy attendees included respected investors Chris Delgado and Nick Petrillo from GOLIATH VENTURES, key supporters of SeedHunter’s journey, adding prestige to the occasion.

While the event primarily focused on unveiling SeedHunter’s latest endeavors with the Marketing Module launch, keynote speakers delivered compelling talks on the platform’s potential to transform the crypto and Web3 landscape. COO Alex Barros provided insights into the brand and the newly introduced Marketing Module, teasing the upcoming SeedHunter Funding Module scheduled for release in June 2024. CEO Junaid Dar introduced the platform’s skilled team and expressed gratitude to the esteemed guests. The evening featured networking opportunities accompanied by engaging music and delightful cuisine.

The SeedHunter team is thrilled with the success of the Marketing Module launch event in Dubai and looks forward to hosting more gatherings to strengthen the Web3 community. They invite you to join them on their journey towards building a more inclusive, secure, and user-centric crypto community. Keep an eye out for the innovative SeedHunter Funding Module unveiling in June 2024, a convergence of innovation and investment.

Media Contact
Company Name: Goliath Ventures, LLC
Contact Person: Chris Delgado
Email: Send Email
Country: United States
Website: https://goliathventuresinc.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SeedHunter Celebrates Launch of Marketing Module with Exclusive Dubai Event